Episurf Medica: Looking past Covid-19 - DNB

Q4 was clearly hit by Covid-19, but we expect things to improve over the coming quarters (although Q1 might still see some negative impact). With society generally re-opening and companies such as Episurf Medical getting better access to customer sites, we believe sales should rise in 2022 and into 2023. Our fair value is SEK3.3–9.3.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_189467.pdf